Extractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses Melissa M. Lewis-Bakker, Yi Yang, Rupali Vyawahare, and Lakshmi P. Kotra Cannabis and Cannabinoid Research, 2019, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0067 Abstract Introduction : Phytocannabinoids, characteristic compounds produced by medical cannabis, interact with cannabinoid (CB) receptors (CB1 and CB2) as well as other receptor systems to exhibit their corresponding pharmacological effects. In their natural form, CBs such as D9-tetrahydrocannabinolic acid and cannabidiolic acid are inactive at these receptors, while their decarboxylated forms (D9 tetrahydrocannabinol and cannabidiol, respectively) are potent ligands at CB receptors. Thus, extraction and [...]
Lire la suiteCBD Gel Promising for Fragile X Syndrome Megan Brooks Medscape, 2019 https://www.medscape.com/viewarticle/913267?nlid=129947_2052&src=WNL_mdplsnews_190524_mscpedit_psyc&uac=292598PZ&spon=12&impID=1974025&faf=1 SAN FRANSICO — A clear transdermal cannabidiol (CBD) gel (ZYN002, Zynerba Pharmaceuticals) improved emotional and behavioral symptoms experienced by children and adolescents with fragile X syndrome in a phase 2 open-label study, the company reports. ZYN002 met its primary endpoint, with patients demonstrating a 46% improvement in the total score on the Anxiety, Depression, and Mood Scale (ADAMS) at week 12 compared to baseline. ZYN002 also led to meaningful improvements in all measures of the Aberrant Behavior Checklist for Fragile X (ABC-FXS), which addresses the key symptoms of fragile X syndrome, including social avoidance, [...]
Lire la suiteMedical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland Aleksi Mikael Markunpoika Hupli Medical Cannabis and Cannabinoids, 2018, 1, 112–118 DOI: 10.1159/000495307 https://www.karger.com/Article/FullText/495307 Abstract : This paper presents a detailed patient case report of a male patient who was diagnosed in adulthood (aged 33) with attention deficit hyperactivity disorder (ADHD) and treated initially with immediate-release methylphenidate (Ritalin® 10 mg twice daily). After experiencing adverse effects from prolonged use of this medication and afterwards other medications that were prescribed as alternatives, the patient discovered that cannabinoid therapeutics (CT) had been experimented inside the EU area to treat patients with [...]
Lire la suiteChemical and Biological Studies of Cannabis sativa Roots Mostafa A. Elhendawy, Amira S. Wanas, Mohamed M. Radwan, Nabil A. Azzaz, ElShahat S. Toson, Mahmoud A. ElSohly Medical Cannabis and Cannabinoids, 2018, 1, 104–111 DOI: 10.1159/000495582 https://www.karger.com/Article/FullText/495582 Abstract : The chemical study of Cannabis sativa roots led to the isolation and identification of 10 compounds. Their chemical structures were unambiguously established on the basis of 1D and 2D NMR spectroscopy and mass spectrometry as friedelan- 3-one (1), epifriedelanol (2), β-sitosterol (3), ergost-5- en-3-ol (4), methyl hexadecanoate (5), pentadecanoic acid (6), 10E-hexadecenoic acid (7), 4-hydroxy 3-methoxybenzaldehyde (8), β-sitosterol-β-D-glucoside (9) and p-coumaroyltyramine (10). Compounds 5–9 were reported for the [...]
Lire la suiteExperimental Endozoochory of Cannabis sativa Achenes John M. McPartland and Steve G. Naraine Medical Cannabis and Cannabinoids, 2018, 1, 96–103 DOI: 10.1159/000492971 https://www.karger.com/Article/FullText/492971 Abstract : The mechanism by which Cannabis sativa dispersed from its center of origin remains an open question. The literature provides many hypotheses, which we review for the first time, but experiments are few. Darwin was interested in zoochory – the transport of plants by animals. He demonstrated endozoochory (transport of seeds via animal digestive systems) of C. sativa achenes (seeds) by carrier pigeons, but he did not quantify achene survival rates. We assessed mammalian endozoochory in a triplicate experiment: feeding C. sativa [...]
Lire la suiteCannabinoid Hyperemesis Joseph V. Pergolizzi Jr., Jo Ann LeQuang, John F. Bisney Medical Cannabis and Cannabinoids, 2018, 1, 73–95 DOI: 10.1159/000494992 https://www.karger.com/Article/FullText/494992 Abstract : Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in which a long-term cannabis user suffers an episode of intractable vomiting that may last days separated by longer asymptomatic periods of weeks or months. Cannabinoids are often utilized for their antiemetic properties, so CHS can be a puzzling condition, and the diagnosis of CHS may be disputed by patients. Unlike other cyclic vomiting syndromes, CHS can be relieved by hot showers or topical capsaicin. Abstinence from cannabinoids causes CHS to resolve, sometimes in [...]
Lire la suiteMedical Cannabis Safe, Effective for Neurologic Symptoms in the Elderly Caroline Cassels Medscape Medical News, 2019 https://www.medscape.com/viewarticle/912624_print PHILADELPHIA — Medical cannabis may be safe and effective in the treatment of a wide range of chronic symptoms related to various neurologic illnesses in elderly patients, early research suggests. In a preliminary study, investigators at the Dent Neurologic Institute in Buffalo, New York, found that the drug provided elderly patients relief from chronic pain, sleep disorders, and anxiety related to diseases such as amyotrophic lateral sclerosis, Parkinson disease, neuropathy, spinal cord damage, and multiple sclerosis. "Our findings show that medical marijuana is well-tolerated in people age 75 and [...]
Lire la suiteThe alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro Jose A. Morales-García, Mario de la Fuente Revenga, Sandra Alonso-Gil, María Isabel Rodríguez-Franco, Amanda Feilding, Ana Perez-Castillo & Jordi Riba Scientific Reports, 2017, 7, 5309 www.nature.com/scientificreports https://www.nature.com/articles/s41598-017-05407-9 DOI:10.1038/s41598-017-05407-9 Abstract : Banisteriopsis caapi is the basic ingredient of ayahuasca, a psychotropic plant tea used in the Amazon for ritual and medicinal purposes, and by interested individuals worldwide. Animal studies and recent clinical research suggests that B. caapi preparations show antidepressant activity, a therapeutic effect that has been linked to hippocampal neurogenesis. Here we report that harmine, tetrahydroharmine and harmaline, the [...]
Lire la suiteThe Trouble with CBD Oil Arno Hazekamp Medical Cannabis and Cannabinoids, 2018, 1, 65–72 DOI: 10.1159/000489287 Abstract In just a few years, cannabidiol (CBD) has become immensely popular around the world. After initially being discovered as an effective self-medication for Dravet syndrome in children, CBD is now sold and used to treat a wide range of medical conditions and lifestyle diseases. The cannabinoid CBD, a non psychoactive isomer of the more infamous tetrahydrocannabinol (THC), is available in a growing number of administration modes, but the most commonly known is CBD oil. There are currently dozens, if not hundreds, of producers and sellers of CBD oils [...]
Lire la suiteIndividual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function Celia J. A. Morgan, Tom P. Freeman, Chandni Hindocha, Grainne Schafer, Chelsea Gardner and H. Valerie Curran Translational Psychiatry, 2018, 8, 181 DOI 10.1038/s41398-018-0191-x https://www.researchgate.net/publication/264860201 Abstract The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects. This study aimed to determine the effects of THC and CBD, both alone and in combination on psychotic symptoms and memory function. A randomised, double-blind crossover design compared the effects of (i) placebo, (ii) THC 8mg, (iii) CBD [...]
Lire la suite